Displaying drugs 11276 - 11300 of 11786 in total
Imgatuzumab
Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer).
Investigational
Matched Description: … Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination …
TT 173
TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental procedures.
Investigational
Matched Description: … TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such …
DP-VPA
DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.
Investigational
Matched Description: … acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a …
Merimepodib
Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.
Investigational
Matched Description: … Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. …
Eprotirome
Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. Eprotirome increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and blood glucose.
Investigational
Matched Description: … Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. …
Pradofloxacin
Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
Vet approved
Matched Description: … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal …
GS-6620
GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection).
Investigational
Matched Description: … GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability …
JNJ-54175446
JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma).
Investigational
Matched Description: … JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to …
SEA-CD70
SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).
Investigational
Matched Description: … SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients …
Methapyrilene
Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Withdrawn
Matched Description: … Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. …
SB-249553
SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.
Investigational
Matched Description: … SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. …
Telisotuzumab vedotin
Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
Investigational
Matched Description: … Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety …
ONO-8539
ONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease).
Investigational
Matched Description: … ONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal …
Reloxaliase
Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
Investigational
Matched Description: … Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from _Bacillus Subtilis_. …
Fonadelpar
Fonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease).
Investigational
Matched Description: … Fonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness …
Otelixizumab
Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that...
Investigational
Matched Description: … Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which …
FT516
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
Matched Description: … It is also a potential therapy for COVID-19. ... This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding …
Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine
Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated to the hepatitis B surface antigen . Virus-like particles (VLPs) are protein-based vaccines that stimulate high immune responses because of the VLPs’...
Investigational
Matched Description: … SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a …
Displaying drugs 11276 - 11300 of 11786 in total